Disease Domain | Count |
---|---|
Neoplasms | 7 |
Hemic and Lymphatic Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
CAR-NKT | 3 |
iNKT cell therapy | 2 |
CAR-T | 2 |
Unknown | 1 |
Gene therapy | 1 |
Top 5 Target | Count |
---|---|
CLDN18.2(Claudin 18.2) | 2 |
CD19(B-lymphocyte antigen CD19) | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunologic cytotoxicity [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Allogeneic CD19-directed CAR-iNKT cells(Arovella) ( CD19 ) | Hematologic Neoplasms More | Preclinical |
OroMist | - | Preclinical |
ALA-101 | Lymphoma More | Preclinical |
ALA-102 | Neoplasms More | Preclinical |
CLDN18.2-CAR-iNKT ( CLDN18.2 ) | Neoplasms More | Preclinical |